Compounds > ecteinascidin 743
Page last updated: 2024-09-02

ecteinascidin 743 and cabozantinib

ecteinascidin 743 has been researched along with cabozantinib in 1 studies

Compound Research Comparison

Studies
(ecteinascidin 743)		Trials
(ecteinascidin 743)		Recent Studies (post-2010)
(ecteinascidin 743)		Studies
(cabozantinib)		Trials
(cabozantinib)		Recent Studies (post-2010) (cabozantinib)
660102404731127716

Protein Interaction Comparison

ProteinTaxonomyecteinascidin 743 (IC50)cabozantinib (IC50)
Epidermal growth factor receptorHomo sapiens (human)1.118
High affinity nerve growth factor receptorHomo sapiens (human)0.0723
Acyl-CoA desaturase 1Rattus norvegicus (Norway rat)0.0013
Proto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)0.1699
Hepatocyte growth factor receptorHomo sapiens (human)0.0791
Mast/stem cell growth factor receptor KitHomo sapiens (human)0.0108
Fibroblast growth factor receptor 1Homo sapiens (human)0.0113
Proto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)0.178
Vascular endothelial growth factor receptor 1 Homo sapiens (human)0.012
Tyrosine-protein kinase receptor UFOHomo sapiens (human)0.5617
Kinesin-1 heavy chainHomo sapiens (human)0.19
Vascular endothelial growth factor receptor 3Homo sapiens (human)0.006
Vascular endothelial growth factor receptor 2Homo sapiens (human)0.3151
Receptor-type tyrosine-protein kinase FLT3Homo sapiens (human)0.8877
Angiopoietin-1 receptorHomo sapiens (human)0.0143
Macrophage-stimulating protein receptorHomo sapiens (human)0.069
Coiled-coil domain-containing protein 6Homo sapiens (human)0.4615
SAFB-like transcription modulatorHomo sapiens (human)0.0013

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Alsafadi, S; Decaudin, D; Etienne, V; Gelmi, MC; Glinkina, K; Jager, MJ; Jochemsen, AG; Kuipers, MJ; Nemati, F; Teunisse, AFAS1

Other Studies

1 other study(ies) available for ecteinascidin 743 and cabozantinib

ArticleYear
Preclinical Evaluation of Trabectedin in Combination With Targeted Inhibitors for Treatment of Metastatic Uveal Melanoma.
    Investigative ophthalmology & visual science, 2022, 12-01, Volume: 63, Issue:13

    Topics: Animals; c-Mer Tyrosine Kinase; Caspase 3; Cell Line, Tumor; Humans; Mice; Trabectedin; Uveal Neoplasms

2022